Simmler, L. D. ym.:In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1.The Journal of Pharmacology and Experimental Therapeutics,2016, 357. vsk, nro 1, s. 134–144.PubMed:26791601doi:10.1124/jpet.115.229765ISSN1521-0103Artikkelin verkkoversio.(englanniksi)
Passie, T. & Benzenhöfer, U.:MDA, MDMA, and other ”mescaline-like” substances in the US military’s search for a truth drug (1940s to 1960s).Drug Testing and Analysis,2018, 10. vsk, nro 1, s. 72–80.PubMed:28851034doi:10.1002/dta.2292ISSN1942-7611Artikkelin verkkoversio.(englanniksi)
Sreenivasan, V. R.:Problems in identification of methylenediony and methoxy amphetamines.The Journal of Criminal Law, Criminology, and Police Science,1972, 63. vsk, nro 2, s. 304–312.doi:10.2307/1142315ISSN0022-0205JSTOR:1142315Artikkelin verkkoversio.(englanniksi)
Kemprai, P. ym.:Review on safrole: identity shift of the ’candy shop’ aroma to a carcinogen and deforester.Flavour and Fragrance Journal,2020, 35. vsk, nro 1, s. 5–23.doi:10.1002/ffj.3521ISSN1099-1026Artikkelin verkkoversio.(englanniksi)
Murnane, K. S. ym.:Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(−)-MDMA trained mice.The Journal of Pharmacology and Experimental Therapeutics,2009, 331. vsk, nro 2, s. 717–723.PubMed:19684254doi:10.1124/jpet.109.156174ISSN0022-3565Artikkelin verkkoversio.(englanniksi)
Hauser, F. M. ym.:Identification of specific markers for amphetamines synthesized from glycidic acid pre‐precursors and retrospective search in German profiling database.Drug Testing and Analysis,2020, 12. vsk, nro 1, s. 41–52.PubMed:31471943doi:10.1002/dta.2686ISSN1942-7603Artikkelin verkkoversio.(englanniksi)
Liechti, M. E. & Vollenweider, F. X.:Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies.Human Psychopharmacology: Clinical and Experimental,2001, 16. vsk, nro 8, s. 589–598.doi:10.1002/hup.348ISSN1099-1077Artikkelin verkkoversio.(englanniksi)
Silins, E. & Copeland, J. & Dillon, P.:Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk.The Australian and New Zealand Journal of Psychiatry,2007, 41. vsk, nro 8, s. 649–655.PubMed:17620161doi:10.1080/00048670701449237ISSN0004-8674Artikkelin verkkoversio.(englanniksi)
Aguilar, M. A. & García-Pardo, M. P. & Parrott, A. C.:Of mice and men on MDMA: A translational comparison of the neuropsychobiological effects of 3,4-methylenedioxymethamphetamine (’Ecstasy’).Brain Research,2020, 78. vsk, s. 209-241.PubMed:31812710doi:10.1016/j.brainres.2019.146556ISSN0006-8993Artikkelin verkkoversio.(englanniksi)
Simmler, L. D. ym.:In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1.The Journal of Pharmacology and Experimental Therapeutics,2016, 357. vsk, nro 1, s. 134–144.PubMed:26791601doi:10.1124/jpet.115.229765ISSN1521-0103Artikkelin verkkoversio.(englanniksi)
Steuer, A. E. ym.:Impact of cytochrome P450 2D6 function on the chiral blood plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in humans.PLOS ONE,2016, 11. vsk, nro 3, s. e0150955.doi:10.1371/journal.pone.0150955ISSN1932-6203Artikkelin verkkoversio.(englanniksi)
Schwaninger, A. E. ym.:Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.Clinical chemistry,2011, 57. vsk, nro 12, s. 1748–1756.PubMed:21980168doi:10.1373/clinchem.2011.172254ISSN0009-9147Artikkelin verkkoversio.(englanniksi)
Papaseit, E. ym.:Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV).Intensive Care Medicine,2012, 38. vsk, nro 7, s. 1239–1240.doi:10.1007/s00134-012-2537-9ISSN1432-1238Artikkelin verkkoversio.(englanniksi)
Stillman, RC ym.:”Characterization of three new psychotomimetics. The Pharmacology of Hallucinogens”,The psychopharmacology of hallucinogens, s. 74–83.Pergamon Press, 1978.ISBN9780080219387Teoksen verkkoversio.(englanniksi)
Sreenivasan, V. R.:Problems in identification of methylenediony and methoxy amphetamines.The Journal of Criminal Law, Criminology, and Police Science,1972, 63. vsk, nro 2, s. 304–312.doi:10.2307/1142315ISSN0022-0205JSTOR:1142315Artikkelin verkkoversio.(englanniksi)
Passie, T. & Benzenhöfer, U.:MDA, MDMA, and other ”mescaline-like” substances in the US military’s search for a truth drug (1940s to 1960s).Drug Testing and Analysis,2018, 10. vsk, nro 1, s. 72–80.PubMed:28851034doi:10.1002/dta.2292ISSN1942-7611Artikkelin verkkoversio.(englanniksi)
Passie, T. & Benzenhöfer, U.:MDA, MDMA, and other ”mescaline-like” substances in the US military’s search for a truth drug (1940s to 1960s).Drug Testing and Analysis,2018, 10. vsk, nro 1, s. 72–80.PubMed:28851034doi:10.1002/dta.2292ISSN1942-7611Artikkelin verkkoversio.(englanniksi)
Murnane, K. S. ym.:Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(−)-MDMA trained mice.The Journal of Pharmacology and Experimental Therapeutics,2009, 331. vsk, nro 2, s. 717–723.PubMed:19684254doi:10.1124/jpet.109.156174ISSN0022-3565Artikkelin verkkoversio.(englanniksi)
Hauser, F. M. ym.:Identification of specific markers for amphetamines synthesized from glycidic acid pre‐precursors and retrospective search in German profiling database.Drug Testing and Analysis,2020, 12. vsk, nro 1, s. 41–52.PubMed:31471943doi:10.1002/dta.2686ISSN1942-7603Artikkelin verkkoversio.(englanniksi)
Silins, E. & Copeland, J. & Dillon, P.:Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk.The Australian and New Zealand Journal of Psychiatry,2007, 41. vsk, nro 8, s. 649–655.PubMed:17620161doi:10.1080/00048670701449237ISSN0004-8674Artikkelin verkkoversio.(englanniksi)
Aguilar, M. A. & García-Pardo, M. P. & Parrott, A. C.:Of mice and men on MDMA: A translational comparison of the neuropsychobiological effects of 3,4-methylenedioxymethamphetamine (’Ecstasy’).Brain Research,2020, 78. vsk, s. 209-241.PubMed:31812710doi:10.1016/j.brainres.2019.146556ISSN0006-8993Artikkelin verkkoversio.(englanniksi)
Simmler, L. D. ym.:In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1.The Journal of Pharmacology and Experimental Therapeutics,2016, 357. vsk, nro 1, s. 134–144.PubMed:26791601doi:10.1124/jpet.115.229765ISSN1521-0103Artikkelin verkkoversio.(englanniksi)
Schwaninger, A. E. ym.:Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.Clinical chemistry,2011, 57. vsk, nro 12, s. 1748–1756.PubMed:21980168doi:10.1373/clinchem.2011.172254ISSN0009-9147Artikkelin verkkoversio.(englanniksi)
Murnane, K. S. ym.:Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(−)-MDMA trained mice.The Journal of Pharmacology and Experimental Therapeutics,2009, 331. vsk, nro 2, s. 717–723.PubMed:19684254doi:10.1124/jpet.109.156174ISSN0022-3565Artikkelin verkkoversio.(englanniksi)
Steuer, A. E. ym.:Impact of cytochrome P450 2D6 function on the chiral blood plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in humans.PLOS ONE,2016, 11. vsk, nro 3, s. e0150955.doi:10.1371/journal.pone.0150955ISSN1932-6203Artikkelin verkkoversio.(englanniksi)
Schwaninger, A. E. ym.:Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.Clinical chemistry,2011, 57. vsk, nro 12, s. 1748–1756.PubMed:21980168doi:10.1373/clinchem.2011.172254ISSN0009-9147Artikkelin verkkoversio.(englanniksi)
Sreenivasan, V. R.:Problems in identification of methylenediony and methoxy amphetamines.The Journal of Criminal Law, Criminology, and Police Science,1972, 63. vsk, nro 2, s. 304–312.doi:10.2307/1142315ISSN0022-0205JSTOR:1142315Artikkelin verkkoversio.(englanniksi)
Silins, E. & Copeland, J. & Dillon, P.:Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk.The Australian and New Zealand Journal of Psychiatry,2007, 41. vsk, nro 8, s. 649–655.PubMed:17620161doi:10.1080/00048670701449237ISSN0004-8674Artikkelin verkkoversio.(englanniksi)
Aguilar, M. A. & García-Pardo, M. P. & Parrott, A. C.:Of mice and men on MDMA: A translational comparison of the neuropsychobiological effects of 3,4-methylenedioxymethamphetamine (’Ecstasy’).Brain Research,2020, 78. vsk, s. 209-241.PubMed:31812710doi:10.1016/j.brainres.2019.146556ISSN0006-8993Artikkelin verkkoversio.(englanniksi)
Papaseit, E. ym.:Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV).Intensive Care Medicine,2012, 38. vsk, nro 7, s. 1239–1240.doi:10.1007/s00134-012-2537-9ISSN1432-1238Artikkelin verkkoversio.(englanniksi)
Karjalainen, K & Pekkanen, N. & Hakkarainen, P.:Suomalaisten huumeiden käyttö ja huumeasenteet: Huumeaiheiset väestökyselyt Suomessa 1992-2018, s. 59–60.THL, 2020.ISBN9789523434417Teoksen verkkoversio.
Kemprai, P. ym.:Review on safrole: identity shift of the ’candy shop’ aroma to a carcinogen and deforester.Flavour and Fragrance Journal,2020, 35. vsk, nro 1, s. 5–23.doi:10.1002/ffj.3521ISSN1099-1026Artikkelin verkkoversio.(englanniksi)
Hauser, F. M. ym.:Identification of specific markers for amphetamines synthesized from glycidic acid pre‐precursors and retrospective search in German profiling database.Drug Testing and Analysis,2020, 12. vsk, nro 1, s. 41–52.PubMed:31471943doi:10.1002/dta.2686ISSN1942-7603Artikkelin verkkoversio.(englanniksi)
Liechti, M. E. & Vollenweider, F. X.:Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies.Human Psychopharmacology: Clinical and Experimental,2001, 16. vsk, nro 8, s. 589–598.doi:10.1002/hup.348ISSN1099-1077Artikkelin verkkoversio.(englanniksi)
Passie, T. & Benzenhöfer, U.:MDA, MDMA, and other ”mescaline-like” substances in the US military’s search for a truth drug (1940s to 1960s).Drug Testing and Analysis,2018, 10. vsk, nro 1, s. 72–80.PubMed:28851034doi:10.1002/dta.2292ISSN1942-7611Artikkelin verkkoversio.(englanniksi)
Sreenivasan, V. R.:Problems in identification of methylenediony and methoxy amphetamines.The Journal of Criminal Law, Criminology, and Police Science,1972, 63. vsk, nro 2, s. 304–312.doi:10.2307/1142315ISSN0022-0205JSTOR:1142315Artikkelin verkkoversio.(englanniksi)
Kemprai, P. ym.:Review on safrole: identity shift of the ’candy shop’ aroma to a carcinogen and deforester.Flavour and Fragrance Journal,2020, 35. vsk, nro 1, s. 5–23.doi:10.1002/ffj.3521ISSN1099-1026Artikkelin verkkoversio.(englanniksi)
Murnane, K. S. ym.:Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(−)-MDMA trained mice.The Journal of Pharmacology and Experimental Therapeutics,2009, 331. vsk, nro 2, s. 717–723.PubMed:19684254doi:10.1124/jpet.109.156174ISSN0022-3565Artikkelin verkkoversio.(englanniksi)
Hauser, F. M. ym.:Identification of specific markers for amphetamines synthesized from glycidic acid pre‐precursors and retrospective search in German profiling database.Drug Testing and Analysis,2020, 12. vsk, nro 1, s. 41–52.PubMed:31471943doi:10.1002/dta.2686ISSN1942-7603Artikkelin verkkoversio.(englanniksi)
Liechti, M. E. & Vollenweider, F. X.:Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies.Human Psychopharmacology: Clinical and Experimental,2001, 16. vsk, nro 8, s. 589–598.doi:10.1002/hup.348ISSN1099-1077Artikkelin verkkoversio.(englanniksi)
Silins, E. & Copeland, J. & Dillon, P.:Qualitative review of serotonin syndrome, ecstasy (MDMA) and the use of other serotonergic substances: hierarchy of risk.The Australian and New Zealand Journal of Psychiatry,2007, 41. vsk, nro 8, s. 649–655.PubMed:17620161doi:10.1080/00048670701449237ISSN0004-8674Artikkelin verkkoversio.(englanniksi)
Aguilar, M. A. & García-Pardo, M. P. & Parrott, A. C.:Of mice and men on MDMA: A translational comparison of the neuropsychobiological effects of 3,4-methylenedioxymethamphetamine (’Ecstasy’).Brain Research,2020, 78. vsk, s. 209-241.PubMed:31812710doi:10.1016/j.brainres.2019.146556ISSN0006-8993Artikkelin verkkoversio.(englanniksi)
Simmler, L. D. ym.:In vitro characterization of psychoactive substances at rat, mouse, and human trace amine-associated receptor 1.The Journal of Pharmacology and Experimental Therapeutics,2016, 357. vsk, nro 1, s. 134–144.PubMed:26791601doi:10.1124/jpet.115.229765ISSN1521-0103Artikkelin verkkoversio.(englanniksi)
Steuer, A. E. ym.:Impact of cytochrome P450 2D6 function on the chiral blood plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its phase I and II metabolites in humans.PLOS ONE,2016, 11. vsk, nro 3, s. e0150955.doi:10.1371/journal.pone.0150955ISSN1932-6203Artikkelin verkkoversio.(englanniksi)
Schwaninger, A. E. ym.:Urinary excretion kinetics of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its phase I and phase II metabolites in humans following controlled MDMA administration.Clinical chemistry,2011, 57. vsk, nro 12, s. 1748–1756.PubMed:21980168doi:10.1373/clinchem.2011.172254ISSN0009-9147Artikkelin verkkoversio.(englanniksi)
Papaseit, E. ym.:Surviving life-threatening MDMA (3,4-methylenedioxymethamphetamine, ecstasy) toxicity caused by ritonavir (RTV).Intensive Care Medicine,2012, 38. vsk, nro 7, s. 1239–1240.doi:10.1007/s00134-012-2537-9ISSN1432-1238Artikkelin verkkoversio.(englanniksi)